These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22231340)

  • 21. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
    Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
    Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-standing paraphilia induced by dopamine agonists in Parkinson's disease.
    Pineau F; Schüpbach M; Corvol JC; Flamand-Rouvière C; Vidailhet M; Roze E
    Mov Disord; 2010 May; 25(7):963-5. PubMed ID: 20461818
    [No Abstract]   [Full Text] [Related]  

  • 24. [Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
    Fuchs G
    Fortschr Med; 1997 Feb; 115(5):43-5. PubMed ID: 9162718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Problematic gambling on dopamine agonists: Not such a rarity.
    Grosset KA; Macphee G; Pal G; Stewart D; Watt A; Davie J; Grosset DG
    Mov Disord; 2006 Dec; 21(12):2206-8. PubMed ID: 17013907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 27. Hiccup secondary to dopamine agonists in Parkinson's disease.
    Lester J; Raina GB; Uribe-Roca C; Micheli F
    Mov Disord; 2007 Aug; 22(11):1667-8. PubMed ID: 17534966
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug-induced impulse control disorders in Parkinson's disease.
    Reiff J; Jost WH
    J Neurol; 2011 May; 258(Suppl 2):S323-7. PubMed ID: 21560063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine receptor agonists in the therapy of Parkinson's disease.
    Foley P; Gerlach M; Double KL; Riederer P
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1375-446. PubMed ID: 15480844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hiccups associated with non-ergoline dopamine agonists in Parkinson's disease.
    Coletti Moja M
    Mov Disord; 2010 Jul; 25(9):1292. PubMed ID: 20310014
    [No Abstract]   [Full Text] [Related]  

  • 34. Dopamine receptor agonists and sleep disturbances in Parkinson's disease.
    Chaudhuri KR; Logishetty K
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S101-4. PubMed ID: 20123546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease: fewer treatment withdrawals with levodopa.
    Prescrire Int; 2015 Dec; 24(166):302. PubMed ID: 26788582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].
    Rascol O
    Rev Neurol (Paris); 1999 Jan; 155(1):35-42. PubMed ID: 10093846
    [No Abstract]   [Full Text] [Related]  

  • 37. Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine.
    Link S; Paulus W; Bandelow B
    Mov Disord; 2009 Dec; 24(16):2431-2. PubMed ID: 19890998
    [No Abstract]   [Full Text] [Related]  

  • 38. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease.
    Drapier D; Drapier S; Sauleau P; Derkinderen P; Damier P; Allain H; Vérin M; Millet B
    Psychiatry Res; 2006 Nov; 144(2-3):241-4. PubMed ID: 17011634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.
    Harada T; Ishizaki F; Horie N; Nitta Y; Yamada T; Sasaki T; Nagakane T; Yasumatsu Y; Nitta K; Katsuoka H
    Hiroshima J Med Sci; 2011 Dec; 60(4):79-82. PubMed ID: 22389951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine agonists, sleep disorders, and driving in Parkinson's disease.
    Uitti RJ; Wszolek ZK
    Adv Neurol; 2003; 91():343-9. PubMed ID: 12442692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.